Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology company focused on neurodegenerative disease treatments, announced that CEO David Stamler, M.D. will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024, at 1:30 p.m. ET (October 18, 2024, at 4:30 a.m. AEDT).
The event will be accessible via a live and archived webcast on Alterity's website under the Investors section: Events and Presentations. The webcast archive will be available for three months.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), un'azienda biotecnologica focalizzata sul trattamento delle malattie neurodegenerative, ha annunciato che il CEO David Stamler, M.D. parteciperà a un fireside chat al 2024 Maxim Healthcare Virtual Summit il 17 ottobre 2024, alle 13:30 ET (18 ottobre 2024, alle 4:30 AEDT).
L'evento sarà accessibile tramite un webcast in diretta e archiviato sul sito di Alterity nella sezione Investitori: Eventi e Presentazioni. L'archivio del webcast sarà disponibile per tre mesi.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), una empresa de biotecnología centrada en tratamientos para enfermedades neurodegenerativas, anunció que el CEO David Stamler, M.D. participará en un fireside chat en el 2024 Maxim Healthcare Virtual Summit el 17 de octubre de 2024, a la 1:30 p.m. ET (18 de octubre de 2024, a las 4:30 a.m. AEDT).
El evento será accesible a través de un webcast en vivo y archivado en el sitio web de Alterity en la sección de Inversores: Eventos y Presentaciones. El archivo del webcast estará disponible durante tres meses.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)는 신경퇴행성 질환 치료에 초점을 맞춘 생명공학 회사로서, CEO David Stamler, M.D.가 2024 Maxim Healthcare Virtual Summit에서 fireside chat에 참여한다고 발표했습니다. 이 행사는 2024년 10월 17일 오후 1시 30분 ET (2024년 10월 18일 오전 4시 30분 AEDT)에 진행됩니다.
이번 행사는 Alterity 웹사이트의 투자자 섹션인 이벤트 및 발표에서 실시간 및 아카이브된 webcast를 통해 접근할 수 있습니다. 웹캐스트 아카이브는 3개월 동안 제공됩니다.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), une entreprise de biotechnologie axée sur les traitements des maladies neurodégénératives, a annoncé que le PDG David Stamler, M.D. participera à un fireside chat lors du 2024 Maxim Healthcare Virtual Summit le 17 octobre 2024 à 13h30 ET (18 octobre 2024 à 4h30 AEDT).
L'événement sera accessible via un webcast en direct et archivé sur le site d'Alterity dans la section Investisseurs : Événements et Présentations. L'archive du webcast sera disponible pendant trois mois.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), ein Biotechnologieunternehmen, das sich auf die Behandlung neurodegenerativer Erkrankungen konzentriert, hat angekündigt, dass CEO David Stamler, M.D. an einem Fireside Chat beim 2024 Maxim Healthcare Virtual Summit am 17. Oktober 2024 um 13:30 Uhr ET (18. Oktober 2024 um 4:30 Uhr AEDT) teilnehmen wird.
Die Veranstaltung ist über ein live und archiviertes Webcast auf der Webseite von Alterity im Bereich Investoren: Veranstaltungen und Präsentationen zugänglich. Das Archiv des Webcasts wird drei Monate lang verfügbar sein.
- None.
- None.
MELBOURNE, Australia and SAN FRANCISCO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, 17 October 2024 at 1:30 p.m. ET in the United States / Friday, 18 October 2024 at 4:30 a.m. AEDT in Australia.
A link to the live and archived webcast may be accessed on the Alterity website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Ana Luiza Harrop
we-aualteritytherapeutics@we-worldwide.com
+61 452 510 255
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
FAQ
When will Alterity Therapeutics participate in the 2024 Maxim Healthcare Virtual Summit?
Who will represent Alterity Therapeutics at the 2024 Maxim Healthcare Virtual Summit?
How can I access the webcast of Alterity Therapeutics' fireside chat?
How long will the archived webcast of Alterity Therapeutics' fireside chat be available?
